EUROASPIRE V Survey on Cardiovascular Disease Prevention and Diabetes
NCT03511885 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1736
Last updated 2019-08-15
Summary
EUROASPIRE is a multicentre European study in coronary patients and individuals at high risk of developing cardiovascular disease (CVD), describing their management through lifestyle and use of drug therapies and providing an objective assessment of clinical implementation of current scientific knowledge. Four EUROASPIRE surveys have been carried out by the European Society of Cardiology so far: EUROASPIRE I in 1995-1997 in nine countries, EUROASPIRE II in 1999- 2000 in 15 countries, EUROASPIRE III in 2006-2009 in 22 countries and EUROASPIRE IV in 2012-2015 in 26 countries. The results showed a wide gap between the recommendations and clinical practice with many patients not achieving the lifestyle and medical risk factors goals for CVD prevention. The fifth EUROASPIRE survey is planned for 2016-2018 to determine in hospital coronary patients and apparently healthy individuals in primary care at high risk of developing cardiovascular disease whether the European and national guidelines on cardiovascular disease prevention have been followed and if the practice of preventive cardiology in EUROASPIRE IV has improved by comparison with those centres which took part in EUROASPIRE I, II, III and IV. This survey will also incorporate an assessment of dysglycaemia and kidney function in all patients. The main outcome measures will be the proportions of coronary and high cardiovascular risk patients achieving the lifestyle, risk factor and therapeutic targets for cardiovascular disease prevention. The data collection will be based on a review of patient medical records and a patient interview and examination at least 6 months and at most 3 years after recruiting event. All countries which participated in the first three surveys will be invited to take part in EUROASPIRE V. This fifth survey will give a unique picture of preventive action by cardiologists and primary care physicians looking after patients with coronary disease and individuals at high CVD risk.
Conditions
Interventions
- OTHER
-
There is no intervention
Sponsors & Collaborators
-
European Society of Cardiology
collaborator NETWORK -
Imperial College London
lead OTHER
Principal Investigators
-
David Wood, PhD · Imperial College London
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-08-23
- Primary Completion
- 2018-12-28
- Completion
- 2018-12-28
Countries
- United Kingdom
Study Locations
More Related Trials
-
Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions
NCT00350038 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs
NCT00970918 ·Status: COMPLETED ·Phase: NA
-
Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
NCT01952392 ·Status: COMPLETED
-
ASA- and Clopidogrel-Responsiveness in Patients With Peripheral Arterial Occlusive Disease and Interventional Procedures
NCT00593762 ·Status: SUSPENDED
-
Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.
NCT00734123 ·Status: UNKNOWN ·Phase: PHASE4
-
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
NCT00508924 ·Status: COMPLETED ·Phase: PHASE2
-
Secondary Prevention of Cardiovascular Disease in the Elderly Trial
NCT02596126 ·Status: COMPLETED ·Phase: PHASE3
-
Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI
NCT04981041 ·Status: UNKNOWN ·Phase: PHASE4
-
Registry of the Combination of Antiplatelet Agents and Anticoagulant in Atrial Fibrillation Patients With a CHA2DS2VASc Score >1 Undergoing Percutaneous Coronary Interventions
NCT03012906 ·Status: UNKNOWN
-
The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)
NCT00250380 ·Status: COMPLETED
-
Anticoagulation for Aortic Bioprosthesis (ANTIPRO)
NCT03807921 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861 ·Status: RECRUITING ·Phase: PHASE3
-
Predictors of Cardiovascular Risk in Covid-19 Patients During Acute Disease and at Short Term Follow-up
NCT04371289 ·Status: COMPLETED
-
Aspirin Responsiveness in Women at Risk for Cardiac Events
NCT00818337 ·Status: COMPLETED ·Phase: PHASE4
-
Prospective Real-world Registry Describing Treatment Regimens
NCT03942913 ·Status: UNKNOWN
-
Vorapaxar on Thrombin Generation and Coagulability
NCT03207451 ·Status: COMPLETED ·Phase: PHASE4
-
Cardiovascular Risk Factors , Complications and Threputic Management Strategies in Patients With Coronary Heart Disease and COVID 19
NCT05092711 ·Status: UNKNOWN
-
Appropriateness of Aspirin Use in Medical Outpatients
NCT03387384 ·Status: UNKNOWN
-
Prevention of Venous Obstruction After Implantation of Cardiac Pacemaker and Defibrillator
NCT02331511 ·Status: UNKNOWN ·Phase: NA
-
Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)
NCT03596502 ·Status: COMPLETED
-
Aspirin Resistance in Coronary Artery Disease
NCT00753935 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation
NCT00296218 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate How Patients Regard the Benefits and Risks of Low-dose Aspirin for the Prevention of Heart and Blood Vessels Disease and for the Prevention of Cancer of the Colon and Rectum
NCT03603366 ·Status: COMPLETED
-
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)
NCT03568916 ·Status: COMPLETED
-
Aspirin Reload Before Percutaneous Coronary Intervention: Reperfusion Indexes Evaluation.
NCT01374698 ·Status: COMPLETED ·Phase: PHASE4